Novo Nordisk A/S : does not intend to make a revised proposal for Ablynx

Novo Nordisk does not intend to make a revised proposal for Ablynx

Bagsværd, Denmark, 29 January 2018 - Novo Nordisk notes the announcement of Sanofi's agreed acquisition of Ablynx. On 8 January, Novo Nordisk announced its proposal to acquire Ablynx for up to EUR 30.50 per share in cash, consisting of EUR 28.00 upfront and EUR 2.50 in Contingent Value Rights.

Novo Nordisk today confirms that it will not be making a revised proposal.

Novo Nordisk looks forward to continuing its productive research collaboration with Ablynx.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,700 people in 77 countries and markets its products in more than 165 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube

Further information Media:

Katrine Sperling	[phone]	[e-mail]
Investors:
Peter Hugreffe Ankersen	[phone]	[e-mail]
Hanna Ögren	[phone]	[e-mail]
Anders Mikkelsen	[phone]	[e-mail]
Christina Kjær	[phone]	[e-mail]
Kasper Veje (US)	[phone]	[e-mail]
Novo Nordisk A/S
Corporate Affairs

Novo Allé	Telephone:	Internet:
2880 Bagsværd	[phone]	www.novonordisk.com
Denmark	CVR no:
24 25 67 90